Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

Ib Clinical Trial of ANA598. Anadys has completed preparations required to initiate a Phase Ib clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection, and expects to initiate patient dosing shortly. ANA598 will be administered to naive genotype 1a and 1b patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a period of three days. Anadys expects to have viral load data from this study in the first quarter of 2009. Based on the data from the first three cohorts, Anadys may elect to explore once daily dosing and/or other dose levels of ANA598.

-- Conclusion of Healthy Volunteer Study in Phase I Clinical Trial of ANA598. In September, Anadys announced preliminary results of the Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in HCV infected patients. ANA598 was well tolerated at all doses tested, and all doses achieved plasma drug concentrations predicted to display substantial antiviral activity based on preclinical data. Safety and PK data from all dose levels in the Phase I clinical trial of ANA598 will be presented in a late-breaker poster session on November 3 at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California. Further preclinical data on ANA598 will be presented at AASLD in two additional poster presentations on November 4.

-- Initiation of Long-Term Chronic Toxicology Studies of ANA598. In September, Anadys initiated long-term chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these and other non-clinical activities into 2008 will enable a more rapid and continuous development path into Phase II studies during 2009.

-- Phase I Clinical Trial of ANA773 in HCV. In July, Anadys announced that it was resuming
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Md. , Sept. 15, 2014   ... leading innovator of scientific products and services for ... One Acquisition Solution for Integrated Services (OASIS) from ... (FAS). GST was selected to provide the government ... the Small Business (SB) category in Pool 4. ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014  iVinci Health LLC, the ... Patient Revenue Management system, branded as VisitPay®, has successfully ... announced the launch of a new extension to VisitPay® ... an easy and convenient way for patients to manage ... owed by them and their families. The ...
(Date:9/15/2014)... , 15 septembre 2014 La ... Week (IPAW) (semaine internationale sur la sensibilisation ... octobre. Initiative conjointe de la Plasma Protein ... sociétés membres , l,IPAW vise à : ... sujet de la collecte du plasma-aphérèse , ...
Breaking Biology Technology:Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3
... , , , , , , ... Amex: NBS ) ("NeoStem" or the "Company"), an international,biopharmaceutical company ... it priced a public offering of 5,000,000 shares of its common ... after underwriting,discounts and commissions and expenses, will be approximately $5,697,500 ...
... , , , SHENYANG, ... Inc. (Nasdaq:, SSRX ) ("3SBio" or "the Company"), a ... manufacturing and marketing,biopharmaceutical products, and Ascentage Pharma Group Corporation, ... strategic,alliance to research, develop and commercialize best-in-class targeted cancer,therapeutics ...
... simple one-step process that produces both n-type and ... use of the promising material for future electronic ... used to increase conductivity in graphene nanoribbons used ... (SOG) material to graphene and then exposing it ...
Cached Biology Technology:NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 2NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 43SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics 23SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics 33SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics 4Single-step technique produces both p-type and n-type doping for future graphene devices 2Single-step technique produces both p-type and n-type doping for future graphene devices 3
(Date:9/15/2014)... the Department of Science and Technology in Society in ... Virginia Tech, has won a 2014 National Science Foundation ... and problems of creating a global nuclear emergency response ... Nuclear Power Plant in March 2011 was a turning ... Schmid said. Three of the plant,s six nuclear reactors ...
(Date:9/15/2014)... of the cheetah: The big predator is the fastest land ... just a few seconds. As it ramps up to top ... it reaches a full gallop. , Now MIT researchers have ... a robotic cheetah a sleek, four-legged assemblage of gears, ... its feline counterpart. The team recently took the robot for ...
(Date:9/15/2014)... no published account where hippopotamuses are demonstrably shown swimming ... water. But if they can,t swim, how did they ... accepted models for the methods, patterns, and timing of ... Crete, and Madagascar) may need to be reconsidered. , ... mainland are not currently supported by positive geological ...
Breaking Biology News(10 mins):'Nuclear disasters don't respect national boundaries' 2Run, cheetah, run 2Run, cheetah, run 3
... shift away from traditional coffee-growing techniques may be increasing ... that has swept through plantations in Central America and ... studies the disease. The current outbreak of coffee ... Mexico since the fungal disease arrived in the region ...
... stations could be drastically reduced by a new, energy-efficient ... releases it when exposed to sunlight. In a ... University and CSIRO scientists for the first time discovered ... of materials known for their exceptional capacity to store ...
... African-American women battling vitamin D deficiencies need the same ... to a recent study accepted for publication in The ... (JCEM). Although women with darker skin tones ... to measure Vitamin D levels, called 25-hydroxyvitamin D or ...
Cached Biology News:Modern growing methods may be culprit of 'coffee rust' fungal outbreak 2Modern growing methods may be culprit of 'coffee rust' fungal outbreak 3Carbon sponge could soak up coal emissions 2African-American, Caucasian women should take identical vitamin D doses 2